Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?

被引:12
|
作者
Demir, Lutfiye [1 ]
Ekinci, Nese [2 ]
Erten, Cigdem [1 ]
Kucukzeybek, Yuksel [1 ]
Alacacioglu, Ahmet [1 ]
Somali, Isil [3 ]
Can, Alper [1 ]
Dirican, Ahmet [1 ]
Bayoglu, Vedat [1 ]
Akyol, Murat [1 ]
Cakalagaoglu, Fulya [2 ]
Tarhan, Mustafa Oktay [1 ]
机构
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, TR-35210 Alsancak, Turkey
关键词
Gastrointestinal stromal tumor; immunohistochemistry; predictive potential; prognosis; IMATINIB MESYLATE; C-KIT; GIST; MUTATIONS; SURVIVAL; RECURRENCE; RESISTANCE; DIAGNOSIS;
D O I
10.7314/APJCP.2013.14.8.4751
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). Materials and Methods: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. Results: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (>= 30%) was significantly associated with shorter OS (34 vs 95.2 months; 95% CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<% 10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that >= 10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. Conclusions: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.
引用
收藏
页码:4751 / 4758
页数:8
相关论文
共 50 条
  • [1] The prognostic significance of ING4 expression on gastric gastrointestinal stromal tumors by immunohistochemistry
    Sahin, Sevinc
    Ekinci, Ozgur
    Seckin, Selda
    Dursun, Ayse
    ANNALI ITALIANI DI CHIRURGIA, 2017, 88 (04) : 311 - 317
  • [2] Gastrointestinal stromal tumors
    Ridolfini, Marco Pericoli
    Cassano, Alessandra
    Ricci, Riccardo
    Rotondi, Fabio
    Berardi, Stefano
    Cusumano, Giacomo
    Pacelli, Fabio
    Doglietto, Giovanni Battista
    ANNALI ITALIANI DI CHIRURGIA, 2011, 82 (02) : 97 - 109
  • [3] Gastrointestinal stromal tumors
    Liegl-Atzwanger, Bernadette
    Fletcher, Jonathan A.
    Fletcher, Christopher D. M.
    VIRCHOWS ARCHIV, 2010, 456 (02) : 111 - 127
  • [4] Clinicopathological and Prognostic Features of Surgical Management in Duodenal Gastrointestinal Stromal Tumors
    Shi, Hong Peng
    Huang, Min Lu
    Wang, Zhen Qiang
    Zheng, Ya Nan
    Zhu, Zheng Lun
    Sah, Birendra Kumar
    Liu, Wen Tao
    Yan, Min
    Zhu, Zheng Gang
    Li, Chen
    DIGESTIVE SURGERY, 2018, 35 (06) : 498 - 507
  • [5] Evaluation of Prognostic Factors and Their Capacity to Predict Biological Behavior in Gastrointestinal Stromal Tumors
    Calabuig-Farinas, Silvia
    Antonio Lopez-Guerrero, Jose
    Navarro, Samuel
    Machado, Isidro
    Poveda, Andres
    Pellin, Antonio
    Llombart-Bosch, Antonio
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2011, 19 (04) : 448 - 461
  • [6] Gastrointestinal Stromal Tumors of the Stomach
    Bennett, Joseph J.
    Rubino, Matthew S.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 21 (01) : 21 - +
  • [7] Gastrointestinal Stromal Tumors: A Review
    Asija, Aakanksha Prasad
    Mejia, Alex V.
    Prestipino, Anthony
    Pillai, Madhavan V.
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (02) : E550 - E557
  • [8] Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors
    Wang, Hao
    Chen, Ping
    Liu, Xin-Xin
    Zhao, Wei
    Shi, Lei
    Gu, Xue-Wen
    Zhu, Chang-Ren
    Zhu, Hai-Hang
    Zong, Liang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [9] Clinicopathological Features and Prognostic Factors of Rectal Gastrointestinal Stromal Tumors
    Xiao, C. C.
    Zhang, S.
    Wang, M. H.
    Huang, L. Y.
    Wu, P.
    Xu, Y.
    Zhu, X. L.
    Sheng, W. Q.
    Du, C. Y.
    Shi, Y. Q.
    Guan, Z. Q.
    Cai, S. J.
    Cai, G. X.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2013, 17 (04) : 793 - 798
  • [10] Prognostic Relevance of KIT and PDGFRA Mutations in Gastrointestinal Stromal Tumors
    Braggio, Esteban
    Braggio, Danielle De Almeida
    Small, Isabele Avila
    Lopes, Lisandro F.
    Valadao, Marcus
    Gouveia, Maria Emmerick
    Moreira, Aline Dos Santos
    Linhares, Eduardo
    Romano, Sergio
    Bacchi, Carlos E.
    Renault, Ilana Zalcberg
    Guimaraes, Denise Peixoto
    Ferreira, Carlos Gil
    ANTICANCER RESEARCH, 2010, 30 (06) : 2407 - 2414